sinc
first
report
individu
new
england
journal
medicin
nearli
million
individu
infect
alon
four
million
peopl
infect
three
million
die
acquir
immunodefici
syndrom
aid
wwwunaidsorg
uniqu
featur
establish
pool
latent
infect
cell
earli
primari
infect
result
indefinit
establish
infect
infect
individu
featur
infect
place
sharp
contrast
almost
viral
infect
initi
round
viral
replic
establish
perman
reservoir
infect
although
infect
individu
remain
healthi
nearli
year
date
singl
spontan
cure
infect
confirm
infect
individu
either
die
remain
infect
therefor
pose
greater
challeng
develop
classic
vaccin
antivir
strategi
gear
ultim
lead
erad
viru
safe
effect
vaccin
stop
spread
yet
develop
possibl
develop
success
vaccin
near
futur
remain
seen
introduct
potent
antiretrovir
therapi
import
achiev
toward
control
infect
aid
see
tabl
therapi
combat
infect
result
dramat
decreas
aidsassoci
morbid
mortal
develop
countri
despit
develop
success
therapeut
strategi
employ
treatment
combin
highli
activ
antiretrovir
therapi
haart
possibl
erad
infect
individu
mainli
due
persist
viral
reservoir
reservoir
erad
even
extend
antiretrovir
therapi
reduc
viremia
undetect
level
viral
rna
copi
per
millilit
plasma
therefor
individu
infect
need
receiv
antiretrovir
therapi
mani
year
life
current
treatment
target
viral
enzym
revers
transcriptas
rt
proteas
well
envelop
glycoprotein
tabl
recent
antiretrovir
approv
clinic
use
block
bind
coreceptor
host
cell
despit
success
potent
combin
regimen
develop
drug
resist
constitut
major
hurdl
toward
longterm
efficaci
current
antiretrovir
therapi
moreov
sever
year
implement
haart
increas
drug
resist
requir
initi
continu
effort
develop
new
drug
therapi
strategi
viral
target
far
antiretrovir
drug
approv
sever
other
clinic
preclin
develop
tabl
current
limit
haart
restrict
drug
resist
toxic
side
effect
hyperlipidemia
hyperglycemia
hypersensit
pancreat
lipoatrophi
anemia
neutropenia
rash
diarrhoea
gastrointestin
distress
insulin
resist
immun
reconstitut
syndrom
renal
dysfunct
hepatotox
increas
risk
liver
cirrhosi
myocardi
infarct
describ
respons
treatment
antiretrovir
drug
moreov
likelihood
side
effect
increas
due
improv
lifespan
result
success
haart
final
coinfect
hepat
c
hepat
b
tuberculosi
malaria
complic
treatment
regimen
infect
individu
limit
challeng
current
antiretrovir
therapi
justifi
continu
effort
develop
new
strategi
fire
et
al
first
discov
introduc
long
doublestrand
rna
dsrna
nematod
caenorhabd
elegan
led
target
degrad
homolog
mrna
reveal
exist
fundament
mechan
known
rnai
gene
express
regul
later
find
elbashir
et
al
show
rnai
also
occur
mammalian
cell
importantli
studi
made
extraordinari
demonstr
cell
transfect
synthet
base
pair
bp
short
interf
rna
sirna
duplex
mediat
rnai
sequencespecif
manner
find
enabl
specif
regul
gene
express
varieti
biolog
system
includ
diseas
cell
review
focu
progress
research
employ
rnai
disrupt
diseas
process
caus
given
exogen
rna
target
without
affect
cellular
function
one
promis
applic
rnai
treatment
infecti
diseas
nevertheless
obstacl
develop
rnaibas
therapeut
agent
one
major
problem
antiretrovir
therapi
emerg
resist
variant
enorm
genom
heterogen
may
hinder
efficaci
singl
defin
sirna
coexpress
multipl
sirna
could
reduc
emerg
singlesirnaresist
virus
effect
compar
achiev
haart
combin
three
drug
treatment
altern
strategi
counter
possibl
sirnaresist
virus
would
target
transcript
cellular
cofactor
essenti
infect
replic
eg
specif
cell
surfac
receptor
side
effect
downregul
cellular
target
long
term
howev
current
unknown
deliveri
remain
major
hurdl
rnai
therapi
sirna
unabl
cross
mammalian
cell
membran
without
aid
genetherapi
vector
capabl
stabli
express
sirna
precursor
although
welldocu
hazard
observ
introduct
foreign
vector
sequenc
chromosom
dna
final
offtarget
effect
target
gene
share
partial
homolog
sirna
stimul
innat
immun
system
need
consid
avoid
although
innat
immun
system
effici
trigger
dsrna
bp
high
concentr
smaller
sirna
may
abl
activ
pathway
nevertheless
evid
activ
innat
immun
system
influenc
degre
specif
sirna
life
cycl
begin
viral
bind
via
viral
envelop
cellular
receptor
conjunct
coreceptor
either
case
tcelltrop
viru
macrophagetrop
viru
fig
infect
cell
immun
system
specif
cell
includ
lymphocyt
monocyt
macrophag
result
absenc
effect
vaccin
therapi
slow
continu
deplet
cell
ensu
progress
toward
aid
fusion
viral
cellular
membran
provid
genom
two
rna
molecul
posit
polar
access
interior
cell
genom
viral
rna
convert
doublestrand
dna
rt
fig
viral
dna
form
preintegr
complex
along
viral
integras
transport
nucleu
dna
integr
host
genom
proviru
replic
divid
earli
late
phase
earli
phase
splice
transcript
encod
two
essenti
protein
tat
rev
synthes
tat
activ
viral
transcript
wherea
rev
interact
revrespons
element
rre
facilit
nuclear
export
unsplic
singli
splice
mrna
late
mrna
encod
remain
viral
protein
includ
gag
pol
env
assembl
cell
surfac
togeth
viral
genom
form
virion
releas
cell
bud
viral
proteas
continu
process
viral
polyprotein
matur
form
condens
viral
genom
rna
core
yield
infecti
particl
fig
soon
demonstr
synthet
sirna
abl
induc
rnai
mechan
mammalian
cell
sever
studi
report
gene
express
replic
ex
vivo
could
inhibit
virusspecif
synthet
sirna
express
sirna
target
earli
late
phase
viru
replic
sirna
sever
compon
gag
env
pol
long
termin
repeat
vif
nef
tat
rev
confirm
effect
target
gene
moreov
cell
macrophag
natur
target
infect
also
found
function
rnai
howev
import
question
aros
pioneer
studi
virionassoci
incom
genom
viral
rna
target
rnai
sinc
capabl
integr
host
genom
well
infect
rest
cell
creat
pool
latent
infect
cell
capac
target
incom
viral
rna
sirna
import
therapeut
implic
fig
possibl
target
incom
viral
genom
rna
virtual
imposs
prevent
format
integr
proviru
result
steril
cell
infect
target
incom
viral
rna
may
sever
advantag
rnai
machineri
would
deal
two
case
superinfect
genom
viral
rna
howev
proviru
establish
sever
thousand
viral
transcript
gener
de
novo
infect
cell
target
degrad
may
difficult
rnai
machineri
data
conflict
whether
rnai
target
incom
genom
viral
rna
infect
particl
sever
studi
report
degrad
incom
rna
genom
cell
transfect
artifici
sirna
stabli
express
sirna
howev
studi
report
absenc
rnaimedi
degrad
genom
viral
rna
sirnastransfect
sirnaproduc
cell
moreov
studi
nonseg
negativestrand
rna
viru
respiratori
syncyti
rsv
show
genom
antigenom
viral
rna
encapsid
viru
nucleocapsid
protein
suscept
sirnamedi
silenc
viral
mrna
highli
suscept
mechan
underscor
effici
specif
sirna
target
gene
complet
known
rnai
effici
known
influenc
local
rna
structur
target
sequenc
randomli
select
sirna
target
sequenc
show
larg
variat
effici
argu
region
genom
viral
rna
might
less
access
sirna
rna
contain
viru
revers
transcript
complex
therefor
sirna
might
effect
other
inhibit
earli
step
viru
replic
recent
exhaust
studi
perform
address
issu
studi
transduct
effici
lentivir
vector
measur
number
success
integr
event
determin
cell
line
stabli
express
sirna
target
nef
sequenc
result
indic
similar
transduct
effici
vector
regardless
presenc
absenc
nef
target
sequenc
genom
moreov
reduc
transduct
effici
observ
presenc
multipl
stabli
express
sirna
target
vector
genom
synthet
sirna
target
nef
transient
transfect
prior
transduct
result
highlight
difficulti
design
therapeut
rnai
strategi
aim
prevent
provir
integr
silenc
tat
factor
must
express
effici
proviru
transcript
occur
may
make
easier
target
viral
transcript
virtu
lower
abund
tat
function
compromis
synthet
sirna
mediat
strong
specif
transient
suppress
gene
express
transient
reduct
gene
express
sirna
sever
restrict
applic
therapeut
set
persist
infect
infect
howev
limit
quickli
overcom
use
plasmid
viral
vector
express
sirna
polymeraseiii
transcript
unit
sens
antisens
strand
sirna
express
two
differ
promot
rnai
trigger
upon
anneal
two
strand
potent
gene
silenc
achiev
sens
antisens
strand
express
singl
transcript
abil
form
duplex
hairpin
structur
inde
replic
could
effici
inhibit
short
hairpin
rna
shrna
stabli
transduc
cell
line
addit
benefit
use
shrna
process
dicer
like
endogen
microrna
mirna
tat
sirna
deliv
premirna
precursor
effect
reduc
antigen
product
tat
sirna
express
convent
shrna
model
shrna
endogen
mirna
increas
antivir
potenc
rnai
discuss
section
exogen
induc
rnai
respons
mammalian
cell
mediat
sirna
shrna
inhibit
replic
result
rais
question
whether
interact
cellular
rnai
machineri
understand
potenti
physiolog
interact
rnai
machineri
could
significantli
contribut
design
effect
rnaibas
therapi
rnai
constitut
key
compon
innat
immun
respons
viral
infect
plant
invertebr
anim
postul
similar
protect
function
mammal
plant
invertebr
anim
long
dsrna
serv
initi
trigger
rnai
mechan
initi
dsrna
process
dicer
sirna
howev
mammalian
cell
long
dsrna
sequenc
bp
length
potent
induc
interferon
ifn
respons
remain
unclear
whether
introduct
long
dsrna
mammalian
somat
cell
capabl
result
product
sirna
nevertheless
rnai
induc
mammalian
cell
nuclear
endogen
express
rna
intermedi
mirna
biogenesi
pathway
ie
sirna
shrna
human
genom
encod
sever
hundr
differ
mirna
molecul
believ
key
player
posttranscript
regul
mani
aspect
cellular
differenti
rnai
postul
exist
mammal
mechan
posttranscript
regul
program
endogen
encod
mirna
rather
involv
intrins
antivir
immun
rna
virus
except
retrovirus
produc
long
dsrna
molecul
infect
cell
repres
essenti
intermedi
genom
rna
product
mani
dna
virus
also
gener
long
dsrna
small
pack
genom
converg
transcript
promot
studi
attempt
identifi
sirna
virusinfect
human
cell
pfeffer
et
al
fail
identifi
viral
sirna
cell
infect
dna
virus
human
cytomegaloviru
kaposi
sarcomaassoci
herp
viru
epsteinbarr
viru
mous
herp
viru
well
rna
virus
yellow
fever
hepat
c
report
howev
identifi
sever
viral
encod
mirna
molecul
dna
viru
contrast
bennass
et
al
report
give
rise
sirna
inhibit
replic
addit
propos
tat
protein
reliev
inhibit
block
function
cellular
dicer
play
key
role
sirna
mirna
biogenesi
moreov
ebola
viru
protein
shown
suppressor
rnai
mammalian
cell
suppressor
activ
function
equival
tat
protein
replac
tat
therebi
support
replic
variant
defici
tat
result
support
hypothesi
rnai
inde
part
innat
antivir
respons
mammalian
cell
howev
recent
report
stabl
express
physiolog
level
tat
global
inhibit
mirna
product
express
infect
human
cell
strong
evid
rnai
part
antivir
innat
immun
plant
come
demonstr
almost
plant
virus
encod
one
suppressor
rna
silenc
sr
protein
target
sever
key
step
rnai
respons
similarli
sever
virus
target
invertebr
specif
nematod
insect
also
encod
sr
protein
flock
hous
viru
member
nodaviru
famili
infect
insect
vertebr
cell
encod
viral
sr
inhibit
dicer
function
evid
controversi
relationship
cellular
rnai
machineri
come
recent
report
triboulet
et
al
provid
evid
physiolog
role
mirnasilenc
machineri
control
replic
studi
show
infect
replic
effici
peripher
blood
mononuclear
cell
donor
latent
infect
cell
knockeddown
dicer
drosha
mirna
process
factor
moreov
activ
suppress
express
polycistron
mirna
cluster
suppress
found
requir
effici
viral
replic
suggest
studi
find
may
help
address
current
challeng
activ
latent
viral
reservoir
therapi
viral
encod
mirna
discov
herp
virus
human
cytomegaloviru
shown
evad
host
immun
system
target
host
gene
viral
encod
mirna
whether
rna
virus
includ
encod
mirna
still
remain
controversi
therapeut
implic
molecular
featur
intrigu
target
viral
mirna
might
constitut
antivir
therapi
mimick
role
could
provid
mean
immunosuppress
therapi
latent
infect
one
import
characterist
requir
vivo
surviv
strain
major
obstacl
erad
viru
infect
haart
recent
studi
show
cellular
mirna
potent
inhibit
product
rest
primari
cell
end
mrna
found
target
cluster
cellular
mirna
includ
enrich
rest
cell
compar
activ
cell
see
chap
specif
inhibitor
mirna
substanti
counteract
effect
target
mrna
combin
mirna
inhibitor
panel
could
use
activ
latent
therapeut
purpos
agreement
former
report
cellular
mirna
shown
capabl
inhibit
hepat
c
viru
replic
infect
mirna
upregul
suggest
cellular
mirna
may
compon
mammalian
innat
immun
respons
review
highlight
evid
show
rnai
provid
robust
method
specif
inhibit
express
target
gene
promis
novel
broadli
applic
approach
antivir
therapi
howev
clinic
applic
rnai
face
sever
challeng
specif
potenti
viral
escap
one
main
advantag
rnai
mechan
highli
sequenc
specif
pioneer
studi
confirm
specif
rnai
evalu
activ
sirna
one
mismatch
rel
target
rna
sequenc
studi
show
mismatch
may
suffici
reduc
silenc
effect
suggest
unspecif
antivir
respons
induc
sirna
involv
silenc
effect
also
show
may
easili
escap
inhibit
sirna
inde
observ
promptli
escap
suppress
effect
sirna
unlik
eukaryot
dna
polymeras
rt
lack
proofread
activ
error
rate
estim
mutat
per
nucleotid
cycl
replic
tabl
one
assum
viral
particl
produc
day
infect
person
must
product
least
replic
cycl
given
length
genom
approxim
nucleotid
high
recombin
rate
like
everi
singl
possibl
point
mutat
like
mani
doubl
mutat
occur
least
day
infect
individu
although
specif
combin
multipl
mutat
may
rare
clear
degre
potenti
genet
chang
drive
diversif
respons
select
pressur
host
immun
respons
antiretrovir
therapi
tabl
strain
diversifi
extens
mutat
recombin
sinc
initi
transmiss
human
mani
decad
ago
central
africa
phylogenet
analysi
numer
isol
obtain
divers
geograph
origin
allow
divis
hiv
type
group
subtyp
subsubtyp
circul
recombin
form
crf
uniqu
recombin
form
urf
divid
three
group
n
sequenc
within
group
account
major
infect
worldwid
fall
limit
number
discret
clade
allow
classif
subtyp
subsubtyp
near
circul
genet
form
group
present
recogn
includ
subtyp
subsubtyp
nearli
crf
divers
subtyp
crf
intersubtyp
mosaic
genom
exacerb
problem
design
effect
sirna
boden
et
al
character
potenc
durabl
virusspecif
rnai
cell
line
stabli
express
shrna
target
transactiv
protein
gene
tat
found
antivir
activ
tat
shrna
abolish
due
emerg
viral
speci
harbor
point
mutat
shrna
target
region
first
three
week
replic
reduc
cell
express
tat
shrna
compar
control
cell
day
howev
viral
titer
increas
indic
loss
tat
shrnamedi
antivir
activ
sequenc
viru
stock
reveal
emerg
viral
speci
contain
nonsynonym
mutat
nucleotid
posit
target
sequenc
da
et
al
use
retrovir
transduct
stabli
introduc
vector
express
sirna
direct
nef
gene
human
cell
escap
variant
resist
sirnanef
appear
sever
week
cultur
rnairesist
virus
contain
point
mutat
doubl
point
mutat
partial
complet
delet
nef
gene
target
sequenc
complet
inactiv
accessori
nef
gene
rel
minor
impact
replic
capac
ex
vivo
interestingli
westerhout
et
al
use
human
cell
stabli
express
sirnanef
target
sequenc
show
also
escap
sirnamedi
nef
inhibit
point
mutat
outsid
target
sequenc
mutat
chang
local
rna
fold
target
sequenc
becom
inaccess
rnai
machineri
recent
sabariego
et
al
show
optim
gene
silenc
sirna
requir
precis
complementar
target
sequenc
substitut
end
partial
toler
viral
escap
simul
systemat
introduc
singlenucleotid
substitut
residu
target
effect
sirna
direct
rt
code
region
mutant
virus
test
replic
better
presenc
sirnart
presenc
wild
type
viru
antivir
activ
sirnart
complet
abolish
singl
substitut
posit
posit
test
substitut
posit
render
nonviabl
virus
except
one
substitut
substitut
either
end
better
toler
rna
interfer
machineri
partial
affect
sirnart
inhibit
sinc
emerg
resist
viru
variant
pose
seriou
problem
use
rnai
therapeut
set
differ
strategi
develop
counteract
viral
escap
one
obviou
strategi
success
inhibit
divers
isol
protect
emerg
viral
escap
would
identifi
viral
conserv
sequenc
target
target
highli
conserv
sequenc
may
hamper
develop
escap
mutant
variant
may
highli
compromis
viral
fit
inde
lee
et
al
target
highli
conserv
vif
sequenc
success
suppress
varieti
primari
viral
isol
five
differ
viral
clade
studi
also
show
toler
target
sequenc
mismatch
may
depend
sequenc
sirna
test
nevertheless
knowledg
variabl
experi
one
decad
antiretrovir
therapi
taught
us
unrealist
tri
target
uniqu
sirna
rapid
develop
resist
occur
high
error
rate
rt
rapid
viral
turnov
mean
nucleotid
target
si
shrna
sever
potenti
escap
variant
alreadi
present
start
therapi
moreov
may
escap
rnai
silent
mutat
case
cost
viral
fit
counteract
strateg
weak
coexpress
multipl
sirna
shrna
target
conserv
rna
sequenc
could
reduc
emerg
singl
sirnaresist
viru
compar
effect
achiev
multipl
antihiv
drug
combin
approach
employ
haart
deliveri
multipl
sirna
could
induc
highli
activ
antiretrovir
gene
silenc
haag
combin
multipl
shrna
conserv
genom
region
effect
inhibit
replic
express
three
differ
shrna
singl
lentivir
vector
result
similar
level
inhibit
per
shrna
compar
singl
shrna
vector
studi
three
shrna
target
gag
pol
code
region
moreov
cell
transduc
doubl
shrna
viral
vector
infect
viru
escap
delay
sever
method
current
use
capabl
express
multipl
effect
sirna
one
possibl
insert
multipl
shrnaexpress
cassett
viral
vector
howev
repeat
regulatori
sequenc
eg
polymeras
iii
promot
may
caus
genet
instabl
reduc
titer
vector
system
moreov
studi
shown
possibl
satur
rnai
pathway
high
level
express
shrna
result
cellular
toxic
particularli
promot
polymeras
iii
promot
use
anoth
approach
use
longhairpin
rna
lhrna
multipl
sirna
produc
lhrna
greater
bp
length
express
cell
creat
multipl
sirna
via
dicermedi
process
without
induc
ifn
pathway
sever
report
describ
effici
rnai
induct
lhrna
nishitsuji
et
al
show
bp
lhrna
conserv
integras
region
suppress
replic
variant
resist
shorter
shrna
target
similarli
lentivir
vector
express
bp
lhrna
target
contigu
sequenc
within
tat
rev
gene
inhibit
viral
replic
nonmut
mutant
variant
altern
target
multipl
conserv
viral
genom
region
use
second
gener
sirna
recogn
mutat
target
site
use
sirna
shrna
target
like
escap
variant
sabariego
et
al
test
second
gener
sirna
compens
fulli
resist
mutat
posit
target
sequenc
nishitsuji
et
al
isol
singl
point
mutat
resist
virus
emerg
lentivir
vector
transduc
cell
express
shrna
region
integras
tat
gene
restor
viral
inhibit
use
second
gener
shrna
match
escap
mutant
use
cell
cultur
infect
determin
target
site
mutat
result
replic
compet
escap
variant
allow
design
sirna
capabl
inhibit
escap
variant
reduc
number
second
gener
sirna
design
strategi
also
target
conserv
region
code
sequenc
new
sirna
also
capabl
induc
rnai
recent
escherichia
coli
endoribonucleas
iii
rnase
iii
mammalian
dicer
use
cleav
dsrna
endoribonucleaseprepar
sirna
esirna
gener
varieti
sirna
effici
specif
target
multipl
site
cognat
rna
studi
esirna
target
rt
code
region
reduc
viral
replic
dose
depend
sequenc
specif
manner
importantli
esirna
obtain
prototyp
rt
sequenc
strain
highli
mutat
rt
sequenc
show
similar
degre
viral
inhibit
suggest
heterogen
popul
esirna
could
overcom
individu
mismatch
rt
sequenc
result
demonstr
abil
esirna
function
potent
inhibitor
moreov
sequenc
target
need
highli
conserv
reach
high
level
viral
replic
inhibit
nevertheless
work
perform
cell
cultur
translat
vivo
set
may
difficult
anoth
recent
explor
strategi
combin
shrna
ribozym
rna
decoy
tripl
combin
lentivir
construct
compris
tar
rna
decoy
snorna
nucleolar
local
promot
shrna
target
tat
rev
promot
chimer
transcleav
hammerhead
ribozym
effici
transduc
human
progenitor
cell
improv
suppress
day
compar
singl
antitatrev
shrna
doubl
combin
shrnaribozym
decoy
tripl
combin
enter
human
clinic
trial
aidslymphoma
patient
use
autolog
hematopoiet
progenitor
cell
target
vector
insert
second
trial
construct
insert
autolog
lymphocyt
like
initi
late
earli
order
prevent
proviru
establish
augment
genet
barrier
viral
escap
cellular
receptor
cofactor
involv
initi
phase
infect
may
target
combin
sirna
shrna
direct
cellular
transcript
may
result
potent
robust
inhibit
viral
replic
nevertheless
target
cellular
cofactor
requir
viru
perform
caution
approach
potenti
harm
host
cell
sever
cellular
factor
involv
lifecycl
explor
possibl
rnai
target
receptor
coreceptor
integr
factor
like
emerin
transcript
factor
cyclin
furin
involv
env
matur
sinc
activ
suppress
express
polycistron
mirna
cluster
suppress
found
requir
effici
viral
replic
nuclear
express
mirna
cluster
may
anoth
altern
inhibit
replic
vivo
suppress
gene
could
limit
due
role
normal
immun
function
make
coreceptor
attract
altern
target
host
protein
may
potenti
coreceptor
target
homozyg
mutat
effect
confer
protect
without
seriou
deleteri
effect
human
immun
function
heterozyg
individu
decreas
surfac
express
lower
plasma
viral
load
substanti
prolong
cours
diseas
potent
noncytotox
shrna
direct
stabli
downregul
introduc
via
hematopoiet
stem
cell
transplant
nonhuman
primat
cell
less
suscept
simian
immunodefici
viru
siv
infect
ex
vivo
recent
sever
antagonist
examin
clinic
trial
abl
reduc
plasma
viral
load
one
order
magnitud
treatment
although
antagonist
hold
great
promis
longterm
toxic
associ
impair
function
remain
address
target
cellular
factor
requir
extens
toxic
studi
deliveri
remain
major
hurdl
rnai
therapi
sirna
unabl
cross
mammalian
cell
membran
without
aid
ex
vivo
transfect
method
use
deliv
sirna
use
vivo
two
strategi
deliv
sirna
vivo
discuss
previou
section
one
stabli
express
sirna
precursor
shrna
viral
vector
use
gene
therapi
technolog
deliv
synthet
sirna
nake
complex
coval
link
sirna
lipid
aptam
peptid
protein
intranas
administr
nake
sirna
either
salin
excipi
dextros
lung
surfact
reduc
viral
load
respiratori
syncyti
viru
rsv
parainfluenza
viru
pediatr
immunocompromis
individu
three
order
magnitud
see
chap
similarli
sirna
intranas
administ
nonhuman
primat
model
sever
acut
respiratori
syndrom
sar
corona
viru
infect
signific
inhibit
viral
replic
lung
studi
clearli
demonstr
util
rnai
treat
viral
respiratori
infect
liposom
vesicl
aqueou
compart
enclos
phospholipid
bilay
fuse
cell
membran
enhanc
drug
deliveri
cell
extens
use
deliv
sirna
vitro
vivo
vitro
transfect
sirna
use
lipidbas
deliveri
agent
routin
laboratori
procedur
lipidbas
formul
effect
deliv
sirna
liver
anim
model
hepat
b
ebola
viru
infect
local
inject
liposom
also
deliv
sirna
effect
target
cell
eye
nervou
system
tumor
topic
deliveri
sirna
use
liposom
may
especi
effect
intravagin
applic
sirna
protect
mice
lethal
herp
simpl
viru
type
sexual
transmit
infect
cervicalvagin
mucosa
main
port
entri
women
thu
effect
topic
microbicid
may
use
prevent
sexual
transmiss
sinc
cellular
coreceptor
requir
infect
major
primari
isol
lipidformul
sirna
transcript
excel
candid
microbicid
sirna
complex
cation
peptid
polym
form
stabl
nanoparticl
via
ionic
interact
neg
charg
phosphat
backbon
similarli
one
studi
show
protamin
antibodi
fusion
protein
deliv
noncoval
bound
sirna
primari
cell
vitro
high
effici
approach
fab
fragment
envelop
antibodi
mediat
receptorspecif
bind
cell
express
envelop
protein
illustr
potenti
antibodi
also
direct
sirna
select
cell
vivo
given
life
cycl
persist
latent
reservoir
rest
infect
cell
make
erad
viru
infect
individu
extrem
difficult
promis
strategi
vivo
deliveri
sirna
use
gene
therapi
approach
predomin
infect
lymphocyt
macrophag
blood
hematopoiet
stem
cell
transplant
could
best
strategi
progeni
cell
would
stabli
express
sirna
downregul
viral
cellular
gene
target
infect
note
infect
rest
nondivid
cell
thu
lentivir
vector
employ
murin
retrovir
vector
lentivir
vector
shown
particularli
suit
transduct
nondivid
cell
hematopoiet
progenitor
cell
vector
seem
prefer
candid
gene
therapi
develop
treatment
individu
howev
shrna
target
highli
conserv
sequenc
may
obstacl
vector
product
report
express
shrna
target
also
deliv
vector
result
reduct
transduct
titer
suggest
shrna
could
crossreact
critic
sequenc
vector
nevertheless
new
lentivir
vector
develop
overcom
issu
vector
backbon
may
modifi
point
mutat
resist
rnaimedi
degrad
vector
product
howev
introduc
rnairesist
mutat
within
lentivir
vector
backbon
add
potenti
risk
transfer
resist
wild
type
genom
one
solut
suggest
would
incorpor
stop
codon
within
vector
sequenc
affect
rnadna
function
yet
would
confer
full
resist
rnai
recombin
result
rnairesist
yet
replicationdefect
variant
due
stop
codon
altern
also
shown
incorpor
target
sequenc
endogen
mirna
within
lentivir
genom
sever
reduc
potenti
recombin
mobil
genom
highli
prone
recombin
recombin
aris
frequent
lentivirus
unlik
murin
retrovirus
prone
integr
distal
promot
within
intron
sequenc
potenti
limit
overal
oncogen
one
main
concern
current
gene
therapi
approach
insert
mutagenesi
preferenti
integr
retrovir
vector
activ
transcrib
gene
includ
protooncogen
led
hematolog
malign
young
individu
sever
immunodefici
scid
diseas
treat
retroviralbas
gene
therapi
problem
could
address
design
vector
integr
specif
welldefin
region
genom
partial
random
insert
transgen
chromosom
dna
hematopoiet
cell
may
induc
clonal
competit
could
potenti
trigger
leukemia
sarcoma
lentivir
vector
deriv
felin
immunodefici
viru
fiv
shown
capabl
stabli
transduc
mani
cell
type
includ
hematopoiet
stem
cell
interestingli
vector
shown
crosspackag
fiv
capabl
stabli
transduc
protect
human
primari
blood
mononuclear
cell
infect
fiv
packag
vector
reduc
likelihood
immun
recognit
seroconvers
due
exposur
structur
protein
continu
effort
focus
produc
effect
safe
hightit
lentivir
vector
deliv
rnai
sever
import
issu
relat
vivo
safeti
toxic
side
effect
warrant
close
attent
rnai
may
consid
valid
altern
treat
infect
diseas
mammalian
cell
dsrna
recogn
dsrna
sensor
tolllik
receptor
tlr
dsrnadepend
protein
kinas
r
pkr
retinoicacidinduc
genei
rigi
compon
innat
immun
system
recognit
lead
activ
ifnregulatori
transcript
factor
nfkb
turn
result
express
ifn
subsequ
activ
transcript
hundr
ifnstimul
gene
isg
jakstat
pathway
mani
isg
encod
protein
antivir
activ
includ
pkr
ifn
respons
play
crucial
role
antivir
immun
vertebr
particularli
rna
virus
gener
dsrna
molecul
life
cycl
ifn
respons
could
significantli
influenc
vivo
applic
sirna
owe
offtarget
effect
toxic
associ
immun
stimul
sirna
molecul
less
bp
length
gener
consid
incap
induc
ifn
pathway
howev
synthet
sirna
formul
nonvir
deliveri
vehicl
potent
induc
ifn
inflammatori
cytokin
vivo
mous
ex
vivo
human
blood
cell
immunostimulatori
activ
formul
sirna
associ
toxic
may
depend
nucleotid
sequenc
although
offtarget
effect
reduc
use
lower
concentr
sirna
ifn
respons
observ
even
low
concentr
studi
emphas
relev
examin
immunostimulatori
effect
potenti
therapeut
sirna
human
immun
cell
prior
clinic
applic
replac
uridin
either
methyl
uridin
abrog
immun
recognit
sirna
tlr
without
compromis
sirna
silenc
potenc
addit
modifi
nucleotid
may
protect
sirna
nucleas
degrad
amelior
pharmacokinet
paramet
vivo
similar
synthet
sirna
endogen
express
shrna
also
activ
ifn
pathway
particular
concern
develop
multipl
shrna
lhrna
approach
molecul
longer
bp
endogen
nuclear
express
shrna
recent
shown
evad
detect
tlr
pkr
integr
progenitor
hematopoiet
stem
cell
endogen
express
lhrna
encod
effect
nefspecif
shrna
capabl
inhibit
product
without
induc
type
ifn
gene
endogen
produc
dsrna
suggest
less
activ
exogen
dsrna
induc
ifn
respons
extend
shrna
eshrna
bp
encod
two
effect
sirna
conserv
sequenc
pol
nef
induc
ifn
respons
eshrna
transfect
cell
simpl
strategi
avoid
activ
ifn
respons
dsrna
describ
modifi
hairpinrna
mhrna
bp
multipl
specif
pointmut
within
sens
strand
transcrib
trna
val
promot
produc
rnai
without
induc
ifn
pathway
gene
express
lhrna
also
appear
well
toler
induc
ifn
gene
activ
vivo
deliv
mice
via
hydrodynam
tailvein
inject
anoth
potenti
side
effect
sirna
shrna
lethal
associ
overdos
previou
studi
mice
treat
high
dose
viral
vector
express
shrna
result
high
copi
number
per
cell
led
fatal
due
oversatur
misirna
pathway
potenti
risk
assess
prior
eventu
clinic
rnai
applic
cell
transduc
singl
vector
copi
avoid
high
express
level
may
induc
unwant
side
effect
overdos
could
also
induc
offtarget
effect
sirna
shrna
silenc
partial
complementari
transcript
mirnalik
mechan
cytotox
effect
shrna
human
lymphocyt
result
overexpress
also
report
risk
advers
effect
sirna
would
increas
situat
shrna
express
maintain
live
organ
long
period
intracellular
immun
addit
transduc
cell
line
differenti
primari
human
cell
rel
differ
hematopoiet
stem
cell
transduc
ultim
gene
therapi
therapeut
set
stem
cell
develop
differ
lineag
express
shrna
could
influenc
develop
suggest
satur
mirna
pathway
may
disturb
hematopoiesi
inde
mirna
involv
regul
gene
control
hematopoiesi
mous
whether
vivo
gene
silenc
sirna
shrna
disrupt
endogen
mirna
pathway
remain
address
recent
target
gene
shown
effect
silenc
mous
hamster
liver
system
administr
synthet
sirna
without
demonstr
effect
mirna
level
activ
sirna
target
two
hepatocytespecif
gene
apolipoprotein
b
factor
vii
administ
mice
achiev
effici
silenc
mrna
transcript
without
signific
chang
level
three
hepatocyteexpress
mirna
moreov
multipl
administr
sirna
target
hepatocyteexpress
gene
scap
hamster
achiev
longterm
mrna
silenc
without
signific
chang
level
studi
may
advanc
use
sirna
safe
therapeut
altern
anoth
potenti
side
effect
sirna
shrna
silenc
cellular
mrna
share
partial
homolog
sirna
shrna
sequenc
mirnalik
mechan
offtarget
effect
requir
complementar
sirna
seed
region
region
target
mrna
effect
sirna
shrna
may
theori
numer
potenti
offtarget
mrna
thu
offtarget
silenc
may
easili
elimin
sirna
sequenc
select
moreov
combin
multipl
shrna
would
increas
number
offtarget
mrna
potenti
affect
offtarget
transcript
silenc
may
limit
specif
sirna
therapeut
applic
one
studi
show
modif
sirna
reduc
sirna
offtarget
effect
similarli
chemic
modif
also
reduc
offtarget
phenotyp
growth
inhibit
studi
key
modif
ribosyl
substitut
posit
guid
strand
reduc
silenc
offtarget
transcript
exhibit
complementar
seed
region
sirna
guid
strand
ex
vivo
select
sirna
verifi
absenc
unwant
offtarget
help
defin
strategi
either
enhanc
avoid
nonspecif
effect
sirna
order
develop
safe
therapeut
studi
appropri
anim
model
also
help
preclin
assess
safeti
efficaci
research
larg
restrict
vitro
ex
vivo
clinic
studi
limit
abil
rapidli
assess
new
strategi
treat
viru
infect
human
gammac
scid
mous
model
sustain
longterm
multilineag
hematopoiesi
capabl
mount
immun
respons
achiev
intraperiton
inject
precursor
cell
newborn
gammac
mous
model
inject
shrnatransduc
cell
result
stabl
express
downmodul
matur
tcell
offspr
infect
mous
model
result
high
viremia
cell
deplet
therefor
vivo
anim
model
andor
other
develop
near
futur
valuabl
evalu
rnaibas
strategi
aim
prevent
treat
infect
discoveri
rnai
provid
us
power
new
tool
biolog
research
drug
discoveri
rnai
current
advanc
basic
research
clinic
trial
also
expand
direct
new
field
therapeut
strategi
potenti
treat
wide
rang
differ
diseas
includ
sever
decad
ago
adapt
immun
allow
possibl
prevent
spread
mani
pathogen
human
virus
nevertheless
discoveri
effect
prevent
therapeut
vaccin
remain
elus
rnai
therapeut
rapidli
arriv
clinic
studi
mani
diseas
includ
sever
current
untreat
difficult
treat
convent
drug
although
promis
studi
result
emerg
recent
year
challeng
remain
whether
rnai
suitabl
treat
prevent
infect
